Claudia-Martina Messow

Claudia-Martina Messow

Auto-generated profile, based on publicly available information

Claudia-Martina Messow

Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2008 in Circulation
Verified
Journal Article
Closed access
PDF file
CEChristine Espinola-Klein
Christine Espinola-Klein
HRHans J. Rupprecht
Hans J. Rupprecht
CBChristoph Bickel
Christoph Bickel
KLKarl Lackner
Karl Lackner
SSSavvas Savvidis
Savvas Savvidis
SBStefan Blankenberg
Stefan Blankenberg
Background— An ankle-brachial index (ABI; ratio of ankle and brachial systolic blood pressure) 1.5 were excluded. We compared patients with ABI <0.9 according to the current definition ( with PAD , n=204 [25.0%]), those with ABI ≥0.9 according to the modified definition ( without PAD , n=524 [64.2%]), and those with ABI <0.9 according to the modified definition and ≥0.9 according to the current definition ( suspected PAD , n=88 [10.8%]). Follow-up data (median 6.6 years) were available for 812 patients (99.5%); 157 patients (19.3%) experienced cardiovascular events (cardiovascular death, myocardial infarction, or stroke). Patients without PAD had the lowest cardiovascular event rate, whereas event rates were comparable for patients with PAD and those with suspected PAD (14.8% versus 28.4% versus 25.0%, respectively). In a fully adjusted Cox regression analysis that included patients without PAD as the reference group, the hazard ratio (95% CI) was 1.56 (0.97 to 2.53) for patients with suspected PAD and 1.67 (1.16 to 2.40) for patients with PAD. Conclusions— When the higher ankle pressure is used for ABI calculation, a group of patients at high risk for cardiovascular events is overlooked. With a simple modification of ABI (use of the lower instead of the higher ankle pressure), more patients at risk could be identified.

28 September 2010 in Diabetes
Verified
Journal Article
Open access
PDF file
MSMakrina Savvidou
Makrina Savvidou
SNScott M. Nelson
Scott M. Nelson
MMMahlatse Makgoba
Mahlatse Makgoba
CMClaudia-Martina Messow
Claudia-Martina Messow
NSNaveed Sattar
Naveed Sattar
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides
OBJECTIVE Predictors of gestational diabetes mellitus (GDM) have been widely studied, but few studies have considered multiple measures. Our objective was to integrate several potential GDM predictors with consideration to both simple and novel measures and to determine the extent to which GDM can be predicted in the first trimester. RESEARCH DESIGN AND METHODS We identified first-trimester maternal samples from 124 women who developed GDM and 248 control subjects who did not. We gathered data on age, BMI, parity, race, smoking, prior GDM, family history of diabetes, and blood pressure. Using retrieved samples, we measured routine (lipids, high-sensitivity C-reactive protein, and γ-glutamyltransferase) and novel (adiponectin, E-selectin, and tissue plasminogen activator [t-PA]) parameters. We determined independent predictors from stepwise regression analyses, calculated areas under the receiver-operating characteristic curves (AUC-ROC), and integrated discrimination improvement (IDI) for relevant models. RESULTS Compared with control subjects, women who subsequently developed GDM were older, had higher BMIs, were more likely to be of Asian origin, had a history of GDM or family history of type 2 diabetes, and had higher systolic blood pressure (P < 0.05 for all). With regard biochemical measures, stepwise analyses identified only elevated t-PA and low HDL cholesterol levels as significant (P ≤ 0.015) independent predictors of GDM beyond simple non–laboratory-based maternal measures. Their inclusion improved the AUC-ROC from 0.824 to 0.861 and IDI by 0.052 (0.017–0.115). CONCLUSIONS GDM can be usefully estimated from a mix of simple questions with potential for further improvement by specific blood measures (lipids and t-PA).

1 February 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
SNScott M. Nelson
Scott M. Nelson
MMMartina C. Messow
Martina C. Messow
AWA. Michael Wallace
A. Michael Wallace
RFRichard Fleming
Richard Fleming
AMAlex McConnachie
Alex McConnachie

1 May 2009 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
MWMarcus Alexander Wörns
Marcus Alexander Wörns
AWArndt Weinmann
Arndt Weinmann
KPKerstin Pfingst
Kerstin Pfingst
CSCarla Schulte-Sasse
Carla Schulte-Sasse
CMClaudia-Martina Messow
Claudia-Martina Messow
PGPeter Robert Galle
Peter Robert Galle
Goals and Background The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. Methods Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. Results Fifteen patients presented without LCI or with LCI Child-Pugh A, 15/4 patients had LCI Child-Pugh B/C. Barcelona Clinic Liver Cancer stage was B/C/D in 4/22/8 patients. During treatment period (median 2.2 mo), therapy was discontinued in 61.8% of patients due to tumor progression (32.3%), death (17.6%), AEs (8.8%), or noncompliance (2.9%). Most common grade 3/4 AEs included liver dysfunction (23.5%), diarrhea (14.7%), increased lipase (8.8%), fatigue (8.8%), and hand-foot skin reaction (5.9%). Worsening liver dysfunction/failure was more frequent (P=0.036) in patients with LCI Child-Pugh B/C compared with patients with maintained liver function (no LCI/LCI Child-Pugh A). Median overall survival was 7.2 months for patients with maintained liver function versus 3.3/3.4 months for patients with LCI Child-Pugh B/C. Conclusions These data do not support the use of sorafenib in patients with LCI Child-Pugh C, and patients with LCI Child-Pugh B should be treated with caution until larger trials provide more safety data and a clinically relevant survival benefit under sorafenib therapy.

1 May 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MDM. Dólleman
M. Dólleman
MFM. J. Faddy
M. J. Faddy
JDJ. van Disseldorp
J. van Disseldorp
YSY. T. van der Schouw
Y. T. van der Schouw
CMC. M. Messow
C. M. Messow
FBF. J. M. Broekmans
F. J. M. Broekmans
Context: Anti-Müllerian hormone (AMH) concentration reflects ovarian aging and is argued to be a useful predictor of age at menopause (AMP). It is hypothesized that AMH falling below a critical threshold corresponds to follicle depletion, which results in menopause. With this threshold, theoretical predictions of AMP can be made. Comparisons of such predictions with observed AMP from population studies support the role for AMH as a forecaster of menopause.\ud \ud Objective: The objective of the study was to investigate whether previous relationships between AMH and AMP are valid using a much larger data set.\ud \ud Setting: AMH was measured in 27 563 women attending fertility clinics.\ud \ud Study Design: From these data a model of age-related AMH change was constructed using a robust regression analysis. Data on AMP from subfertile women were obtained from the population-based Prospect-European Prospective Investigation into Cancer and Nutrition (Prospect-\ud EPIC) cohort (n � 2249). By constructing a probability distribution of age at which AMH falls below a critical threshold and fitting this to Prospect-EPIC menopausal age data using maximum likelihood, such a threshold was estimated.\ud \ud Main Outcome: The main outcome was conformity between observed and predicted AMP.\ud Results: To get a distribution of AMH-predicted AMP that fit the Prospect-EPIC data, we found the critical AMH threshold should vary among women in such a way that women with low age-specific AMH would have lower thresholds, whereas women with high age-specific AMH would have higher\ud thresholds (mean 0.075 ng/mL; interquartile range 0.038–0.15 ng/mL). Such a varying AMH threshold for menopause is a novel and biologically plausible finding. AMH became undetectable (�0.2 ng/mL) approximately 5 years before the occurrence of menopause, in line with a previous report.\ud \ud Conclusions: The conformity of the observed and predicted distributions of AMP supports the hypothesis that declining population averages of AMH are associated with menopause, making AMH an excellent candidate biomarker for AMP prediction. Further research will help establish the accuracy of AMH levels to predict AMP within individuals.\u

9 February 2008 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RSRenate Schnabel
Renate Schnabel
CMClaudia M. Messow
Claudia M. Messow
ELEdith Lubos
Edith Lubos
CEChristine Espinola-Klein
Christine Espinola-Klein
HRHans J. Rupprecht
Hans J. Rupprecht
SBStefan Blankenberg
Stefan Blankenberg
In primary prevention, the adipocytokine adiponectin seems to be protective against diabetes mellitus and cardiovascular disease. Data in patients with manifest coronary artery disease (CAD) are scant stimulating the investigation of the association of adiponectin concentrations and cardiovascular outcome in a prospective CAD cohort. In 1890 consecutive patients with documented CAD [1130 with stable angina (SAP) and 760 with acute coronary syndrome (ACS)] baseline concentrations of adiponectin were measured by enzyme-linked immuno assay. During a median follow-up of 2.5 years cardiovascular events were registered (cardiovascular deaths 70; non-fatal myocardial infarction 46). Baseline adiponectin concentrations were similar in patients presenting with SAP [9.03 µg/mL (6.7, 13.45)] or ACS [9.19 µg/mL (6.72, 13.15)], P = 0.779. Kaplan–Meier survival analysis showed a stepwise decrease in event-free survival across quartiles of adiponectin baseline concentration (Plog rank = 0.0188). A similar pattern was observed in both subgroups of patients (SAP P = 0.075 and ACS P = 0.254). In univariate analyses, continuous adiponectin concentration was related to event-free survival in all patients [HR 1.02 (95% confidence interval 1.0–1.04), P = 0.012] as well as in the subgroup of SAP subjects [1.03 (1.01–1.05), P = 0.012]. The relation was less strong in the subgroup presenting with ACS [1.014 (0.99–1.04), P = 0.280]. A correlation of adiponectin with high density cholesterol (r = 0.39) and a negative relation to triglyceride levels (r = −0.22) could be described. An increase of one interquartile distance in adiponectin concentration was associated with a 1.17-fold risk for future cardiovascular events (P = 0.013), in B-type natriuretic peptide (BNP) it meant a 1.13-fold risk (P < 0.001). In the overall patient group, this risk association remained robust after the adjustment for classical risk factors, clinical presentation and cardiac medication. Only after adjustment for BNP adiponectin lost its independent predictive value. In contrast to studies including initially healthy individuals, the current prospective study demonstrates that adiponectin is associated with adverse cardiovascular outcome in patients with manifest CAD.